Bashkim Kadriu, M.D. is a board-certified psychiatrist and neuroscientist at the Experimental Therapeutics and Pathophysiology Branch (ETPB), National Institute of Mental Health (NIMH). His research interests include the neurobiological correlates of treatment-resistant mood disorders with a particular emphasis on discovering biosignatures that guide novel fast-acting antidepressant actions.
All Sessions by Bashkim Kadriu
Thursday 3 October
Workshop: Neurobiological and clinical characterization approaches for developing novel therapeutics for treatment-resistant depression
13:00 - 14:30
Chairs: Alan Frazer, UT Health San Antonio, USA and Thanasios Douzenis, National and Kapodistrian University of Athens, Greece
13:00-13:15: Towards clinical applications of fMRI - replicating global brain connectivity in treatment resistant depression. Christoph Kraus, National Institute of Mental Health, USA
13:20-13:35 Developing imaging markers of depression and treatment response. Jennifer Evans, National Institute of Mental Health, USA
13.40-13:55 Identification of neuroinflammatory markers via metabolomic profiling of a ketamine or placebo crossover trial in patients with treatment-resistant mood disorders. Bashkim Kadriu, National Institute of Mental Health, USA
14:00-14:15 Development of next generation seizure therapy for treatment resistant depression. Zhi-De Deng, National Institute of Mental Health, USA
14:20-14:30 Synopsis and outlook in developments. Discussant: Carlos Zarate, National Institute of Mental Health, USA
CINP2019 is a 2.5-day international meeting that will feature plenaries, meet the expert sessions, satellite symposia as well as interactive educational workshops.
Keep up to date with Conference News & Alerts. Sign Up
International Conference Services GmbH
Gonzagagasse 17, 1010 Vienna, Austria